DK1230268T3 - Heteroklitiske analoger af klasse I-epitoper - Google Patents

Heteroklitiske analoger af klasse I-epitoper

Info

Publication number
DK1230268T3
DK1230268T3 DK00979208.6T DK00979208T DK1230268T3 DK 1230268 T3 DK1230268 T3 DK 1230268T3 DK 00979208 T DK00979208 T DK 00979208T DK 1230268 T3 DK1230268 T3 DK 1230268T3
Authority
DK
Denmark
Prior art keywords
epitopes
class
analogs
heteroclitic analogs
wild
Prior art date
Application number
DK00979208.6T
Other languages
English (en)
Inventor
Glenn Ishioka
Alessandro Sette
Shabnam Tangri
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Application granted granted Critical
Publication of DK1230268T3 publication Critical patent/DK1230268T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00979208.6T 1999-11-18 2000-11-20 Heteroklitiske analoger af klasse I-epitoper DK1230268T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16652999P 1999-11-18 1999-11-18
US23900800P 2000-10-06 2000-10-06
PCT/US2000/031856 WO2001036452A2 (en) 1999-11-18 2000-11-20 Heteroclitic analogs of class i epitodes

Publications (1)

Publication Number Publication Date
DK1230268T3 true DK1230268T3 (da) 2010-02-08

Family

ID=26862329

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00979208.6T DK1230268T3 (da) 1999-11-18 2000-11-20 Heteroklitiske analoger af klasse I-epitoper

Country Status (9)

Country Link
US (2) US8741576B2 (da)
EP (2) EP1230268B1 (da)
JP (2) JP4776131B2 (da)
AT (1) ATE445643T1 (da)
AU (1) AU1661201A (da)
CA (1) CA2386341A1 (da)
DE (1) DE60043158D1 (da)
DK (1) DK1230268T3 (da)
WO (1) WO2001036452A2 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
EP1200109A4 (en) * 1999-07-19 2005-06-15 Epimmune Inc USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
DK1230268T3 (da) 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP1619207A3 (en) * 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1 binding peptides derived from HCV and their uses
US8802618B2 (en) * 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
AU2003221831A1 (en) * 2002-04-05 2003-10-27 Epimmune Inc. Heteroclitic analogs and related methods
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
US8354380B2 (en) * 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
CN100402551C (zh) * 2006-04-14 2008-07-16 中国科学院长春应用化学研究所 β2-微球蛋白的抗原表位及应用
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2015153969A1 (en) 2014-04-04 2015-10-08 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for t cell receptors
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
IL294014B1 (en) 2015-10-23 2024-03-01 Harvard College Nucleobase editors and their uses
MX2018010061A (es) 2016-02-23 2019-07-04 Immune Design Corp Preparaciones de vectores retrovirales de genomas multiples, y metodos y sistemas para producir y usar las mismas.
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
SG11201901979SA (en) * 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
MX2019004692A (es) 2017-01-06 2019-11-08 Eutilex Co Ltd Anticuerpos 4-1bb anti-humano y usos de los mismos.
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) * 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR20190130613A (ko) 2017-03-23 2019-11-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
CA3081710A1 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
EP3942040A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
IL63224A (en) 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4487715A (en) * 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
WO1992002543A1 (en) 1990-08-01 1992-02-20 Cytel Corporation Novel immunosuppressant peptides
CA2101065A1 (en) 1991-01-22 1992-07-23 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
IL102964A0 (en) 1991-08-26 1993-01-31 Cytel Corp Hla-restricted hepatitis b virus ctl epitopes
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6037135A (en) 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US20030152580A1 (en) 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
EP0637335B1 (en) * 1992-04-21 2007-07-25 Institut Pasteur Recombinant mutants for inducing specific immune responses
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US20020098197A1 (en) * 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
US20020177694A1 (en) 1996-01-23 2002-11-28 Alessandro Sette Hla binding peptides and their uses
IL106610A0 (en) 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
WO2001000225A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
US5662907A (en) * 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
ATE466869T1 (de) * 1993-03-05 2010-05-15 Epimmune Inc Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
ES2318848T3 (es) 1993-09-14 2009-05-01 Pharmexa Inc. Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1996022067A2 (en) 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
ES2367640T3 (es) * 1996-03-11 2011-11-07 Epimmune Inc. Péptidos con afinidad de unión aumentada para al menos tres moléculas de tipo hla-a3.
DK0900380T3 (da) 1996-04-26 2003-11-03 Seed Capital Investments Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
JP2001509677A (ja) * 1997-01-31 2001-07-24 エピミューン，インコーポレイティド Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞
JP2002507397A (ja) * 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用
US6632435B1 (en) * 1999-10-20 2003-10-14 City Of Hope CTL epitope analogs
DK1230268T3 (da) 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper

Also Published As

Publication number Publication date
JP4776131B2 (ja) 2011-09-21
EP2177534A3 (en) 2010-07-14
EP2177534A2 (en) 2010-04-21
ATE445643T1 (de) 2009-10-15
EP1230268A2 (en) 2002-08-14
US20090169574A1 (en) 2009-07-02
WO2001036452A3 (en) 2002-01-10
JP2003521243A (ja) 2003-07-15
AU1661201A (en) 2001-05-30
EP1230268B1 (en) 2009-10-14
JP2011101654A (ja) 2011-05-26
CA2386341A1 (en) 2001-05-25
WO2001036452A2 (en) 2001-05-25
DE60043158D1 (de) 2009-11-26
US8741576B2 (en) 2014-06-03
US20030143672A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DK1230268T3 (da) Heteroklitiske analoger af klasse I-epitoper
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
DE69836588D1 (de) Tuberkulose impfstoff
DK0633313T3 (da) Vaccine mod Lyme-sygdom
PL1654355T3 (pl) Warianty polipeptydów Pseudomonas o aktywności niemaltogennej egzoamylazy i ich zastosowanie do wytwarzania produktów żywnościowych
DK1282702T3 (da) Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
DE69834136D1 (de) Gefrierschutzprotein
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
DK1383874T3 (da) Varianter af lipogygenase og deres anvendelse
ATE495247T1 (de) Chromoprotein und fluoroproteine
ATE403729T1 (de) Frostschutzproteine aus basidiomyceten
ATE378408T1 (de) Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren
SE8702272D0 (sv) A fibrnectin binding protein as well as its preparation
DK1501936T3 (da) Familie af cytokin-proteiner
FI910398A (fi) Rekombinant coccidiosisvaccin -5-7-eimeria-ytantigen.
DE69737476D1 (de) Neuer galaninrezeptor
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
SE8604991D0 (sv) Snake venom growth arresting peptide
WO1998040497A3 (en) An ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method
ATE98962T1 (de) Menschliche rhinoviruspeptide.
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
DK145988D0 (da) Genteknologisk fremstillet 140 kd-antigen af plasmodium falciparum og dettes anvendelse
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ATE489463T1 (de) Polypeptid mit einer delta-5-fettsäure- desaturierungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon.
LV12722A (lv) Prv-1 gene and the use thereof